OR WAIT null SECS
© 2023 MJH Life Sciences™ and Formulary Watch. All rights reserved.
Recent FDA action (through March 2010) related to CPI-300, Ondansetron, Intravenous acetaminophen, Gabapentin enacarbil, Rifaximin, ENMD-2076, Ap301, CM-AT, Fingolimod, Nilotinib.
Complete response
Recommendations for approval
Orphan drug designations
Priority review